Adults diagnosed with epilepsy face roughly six times the risk of developing young-onset dementia before age 65 compared with the general population, according to a nationwide study published in Neurology, though researchers emphasize that the absolute 10-year risk remains low at approximately 2.2%.
In Plain English: The Clinical Takeaway
- Absolute Risk vs. Relative Risk: While having epilepsy multiplies the statistical odds of developing early cognitive decline, the actual chance of an individual patient developing young-onset dementia over a decade is still small.
- Cardiovascular Complications: Patients diagnosed with both epilepsy and dementia present a significantly higher prevalence of multimorbidity, particularly cardiovascular conditions such as hypertension.
- Preventative Screening: Clinical care may need to adapt by incorporating early cognitive risk assessments directly into routine, long-term neurology follow-up care.
Nationwide Analyses in France and Sweden Quantify Dementia Risk
Researchers evaluated health registry data across hundreds of thousands of individuals using two distinct epidemiological approaches to untangle the complex relationship between seizure disorders and cognitive decline. While prior clinical literature suggested that each condition may increase the risk for the other, particularly in older adults, significantly less data previously existed regarding young-onset dementia (YOD), which manifests before the age of 65.
A study exploring the epilepsy & young-onset dementia (YOD) association in France & Sweden found a strong association, with epilepsy conferring a higher risk for YOD in midlife. Findings support epilepsy inclusion in YOD risk stratification & prevention. https://t.co/3u6X7g0EhI pic.twitter.com/tj8dtCnmU6
The first investigative method utilized case-control designs in both France and Sweden to look backward at patient histories. The French arm examined 11,360 individuals aged 40 to 64 with a YOD diagnosis and compared them against 113,600 matched controls. Results demonstrated that 12.5% of people with YOD carried a prior epilepsy diagnosis, compared with just 1.2% of individuals without dementia. After adjusting for potential confounders such as stroke, mood disorders, and traumatic brain injury, investigators found that epilepsy was associated with nearly four times the odds of developing young-onset dementia (adjusted odds ratio [aOR], 3.76).
Antiseizure medication (ASM) use was similarly prevalent, recorded in 26.5% of the French YOD cohort versus 10.3% of controls (aOR, 1.44). However, study authors cautioned that medication use alone does not establish causation or prove that specific therapies drive cognitive impairment. A replication study utilizing Swedish national registry data encompassing 16,433 YOD cases and 164,330 matched controls yielded consistent findings.
Tracking Incidence and Comorbidities Over a Ten-Year Horizon
To evaluate the temporal progression of risk, the research team conducted a retrospective cohort study tracking adults with newly diagnosed and previously diagnosed epilepsy across France. Participants ranged in age from 30 to 55 at baseline, with a mean age of 44 years. Over a 10-year follow-up period, the cumulative incidence of young-onset dementia reached 2.20% among adults with newly diagnosed epilepsy and 1.74% for those with prior diagnoses, contrasted with 0.21% in controls without epilepsy.
Adjusted hazard ratios confirmed a persistent, significant elevation in risk for both newly diagnosed (HR, 6.02) and previously diagnosed (HR, 5.38) patient populations. Notably, risk stratification scaled sharply alongside accumulating medical conditions. Among adults with newly diagnosed epilepsy and four or more baseline comorbidities, the 10-year cumulative incidence of YOD climbed to 9.10%, compared with just 1.40% among patients presenting with no other concurrent health issues.
| Patient Cohort | Sample Size (N) | 10-Year Cumulative YOD Incidence | Adjusted Hazard Ratio / Odds Ratio |
|---|---|---|---|
| Newly Diagnosed Epilepsy | 12,901 | 2.20% | HR, 6.02 |
| Prevalent / Prior Epilepsy | 64,083 | 1.74% | HR, 5.38 |
| French YOD Case-Control | 11,360 cases / 113,600 controls | Not Applicable (Case-Control) | aOR, 3.76 (Epilepsy) |
Cardiovascular disease emerged as a prominent overlapping factor, documented in 44.4% of patients who developed both epilepsy and dementia, compared with 20.6% of those who developed dementia in the absence of epilepsy.
Integrating Prevention Into Long-Term Neurology Follow-Up
Vincent Navarro, MD, PhD, of Sorbonne University in Paris, France, highlighted the clinical implications of these registry analyses. “These results support integrating dementia prevention into the care of people with epilepsy,” Navarro stated. Patients may derive substantial benefit from earlier cognitive risk evaluations and intensified management of modifiable vascular drivers, such as high blood pressure.
Investigators stressed that causal pathways remain to be clarified, leaving open the question of whether epileptic activity contributes to dementia or whether both conditions arise from shared underlying factors. The research was limited by an absence of detailed clinical data, potential surveillance bias wherein cognitive decline might be detected more readily in patients with epilepsy, and uncertainty about whether the findings apply beyond France and Sweden.
Contraindications & When to Consult a Doctor
Patients managing epilepsy or antiseizure therapies should consult a qualified neurologist or primary care physician regarding any concerns about cognitive shifts or memory lapses. Individuals experiencing progressive cognitive shifts or executive dysfunction should consult a qualified neurologist or primary care physician for comprehensive neuropsychological evaluation. Particular vigilance is warranted for patients managing concurrent cardiovascular diseases, hypertension, or multiple chronic health conditions.
References
- Neurology: Epilepsy’s Link to Early Dementia (October 14).
- Epilepsy Action: Reporting on early-onset dementia incidence and multi-country registry findings.
